secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0000950170-22-004087
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022
------------------------------------------------------------------------------

- Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).
- Cash and investments $240.2M as of Dec 31, 2021; cash runway into 2H 2023.
- R&D expenses $63.4M full year; G&A $23.0M; non-cash stock-based comp $14.5M.
- NKX101 Phase 1 monotherapy data (AML/MDS) expected 1H 2022; NKX019 data in 2022.
- NKX101 received FDA orphan drug designation for AML; protocol amendments filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/0000950170-22-004087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/nktx-20220317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer